Medifast Beats Earnings, Stock Surges

Medifast surpasses Wall Street expectations in Q1 2026, with revenue of $76M, a 34% drop from last year, and a GAAP loss of $0.19 per share, significantly better than expected. Full-year guidance is robust, with revenue projected at $285M and EPS at $2.15, crushing expectations. However, next quarters outlook is softer, missing estimates by 6%. The stock rose 3% post-earnings, closing at $10.95, with a market cap of $113M. CEO Dan Chard emphasized progress in their metabolic health initiative. Despite recent challenges, these beats and positive long-term outlook suggest cost-cutting and growth positioning, keeping investors engaged. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/ae69f47d4816dece